当前位置: 首页 >> 检索结果
1061. Inhaled corticosteroid improves bronchial reactivity and decreases symptoms in patients with mitral stenosis.
作者: G Cieslewicz.;G Juszczyk.;J Foremny.;E Hamelmann.;Z Religa.;M Zembala.;E W Gelfand.
来源: Chest. 1998年114卷4期1070-4页
To determine if treatment with inhaled budesonide forte can diminish increased bronchial hyperreactivity and improve symptoms in patients with mitral valve stenosis.
1062. Effects of cysteinyl-leukotriene receptor antagonist, thromboxane A2 receptor antagonist, and thromboxane A2 synthetase inhibitor on antigen-induced bronchoconstriction in patients with asthma.
Leukotriene (LT) and thromboxane A2 (TXA2) receptor antagonists have been used in the treatment of asthma.
1063. Systemic bioactivity profiles of oral prednisolone and nebulized budesonide in adult asthmatics.
Because nebulized budesonide may be used as an alternative to maintenance oral prednisolone in the treatment of severe chronic asthma, it is important to compare these two drugs to determine their relative systemic bioactivity profiles in terms of effects on adrenal, bone, and hematologic markers.
1064. Comparison of the flutter device to standard chest physiotherapy in hospitalized patients with cystic fibrosis: a pilot study.
A preliminary study comparing the efficacy and safety of the flutter device (Flutter) to standard, manual chest physiotherapy (CPT) in hospitalized cystic fibrosis (CF) patients undergoing an acute pulmonary exacerbation.
1065. Inspiratory flow rate and dynamic lung function in cystic fibrosis and chronic obstructive lung diseases.
作者: P S Sarinas.;T E Robinson.;A R Clark.;J Canfield.;R K Chitkara.;R B Fick.
来源: Chest. 1998年114卷4期988-92页
The peak inspiratory flow rates (PIFRs) generated by cystic fibrosis (CF) and COPD patients through a range of clinically relevant resistances have not yet been reported (to our knowledge). The objectives of this study were to (1) explore a relevant range of resistive loads and address whether patients with stable CF and COPD can generate the PIFR sufficient to disperse dry-powder inhalants (DPI) and (2) determine whether the optimal inspiratory flow rate effective for delivery of aerosolized pharmacologic therapeutic agents can be attained with a comfort rating acceptable to subjects.
1066. Comparison of the Maxair Autohaler to wet nebulizer in patients with acute asthma.
Patients with acute asthma often have difficulty using a conventional metered-dose inhaler. The Maxair Autohaler (3M Pharmaceuticals; St. Paul, MN) is a hand-held breath-actuated device developed to help patients coordinate drug administration. The study objective is to compare the efficacy of the Autohaler with inhaled beta-agonist administered by wet nebulizer in treating acute asthma exacerbations.
1067. A comparison of triamcinolone acetonide MDI with a built-in tube extender and beclomethasone dipropionate MDI in adult asthmatics.
In this study, the efficacy and safety of triamcinolone acetonide (TA) metered-dose inhaler with a built-in tube extender and beclomethasone dipropionate (BDP) metered-dose inhaler without a spacer device were compared. Both treatments were dosed at their most commonly used daily doses (within labeling).
1068. Effect of exposure to low levels of ozone on the response to inhaled allergen in allergic asthmatic patients.
作者: N A Hanania.;S M Tarlo.;F Silverman.;B Urch.;N Senathirajah.;N Zamel.;P Corey.
来源: Chest. 1998年114卷3期752-6页
In a previous study published by our group, six out of nine subjects with mild allergic asthma were shown to have an enhanced response to allergen challenge following a 1-h exposure in an 0.8-m3 exposure chamber (modified from a body plethysmograph) to an average of 120 parts per billion (ppb) ozone at rest. Other studies failed to confirm this effect. In the present study, using a similar design, we reexamined this effect using a larger group of asthmatics and a larger chamber allowing minimal fluctuations in ozone levels during exposures.
1069. Cardiac effects of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrhythmias and hypoxemia.
作者: M Cazzola.;F Imperatore.;A Salzillo.;F Di Perna.;F Calderaro.;A Imperatore.;M G Matera.
来源: Chest. 1998年114卷2期411-5页
There are several reports of documented adverse cardiac effects during treatment with beta-agonists. Since one should be aware that this may be a problem in patients with preexisting cardiac disorders, we have conducted a randomized, single-blind, balanced, crossover, placebo-controlled study to assess the cardiac effects of two single doses of formoterol (12 microg and 24 microg) and one single dose of salmeterol (50 microg) in 12 patients suffering from COPD with preexisting cardiac arrhythmias and hypoxemia (PaO2<60 mm Hg).
1070. Hemodynamic, cardiac, and electrolyte effects of low-dose aerosolized terbutaline sulfate in asthmatic patients.
Aerosolized beta2-agonists have been associated with increased morbidity in asthmatics. These drugs cause transient increases in heart rate and decreases in serum potassium levels after these drugs are first utilized. This study is designed to elucidate whether beta-adrenergic tolerance to the hemodynamic, cardiac, and electrolyte effects of inhaled terbutaline occurs during 14 days of maintenance therapy.
1071. Influence of beclomethasone and salmeterol on the perception of methacholine-induced bronchoconstriction.
作者: L P Boulet.;H Turcotte.;A Cartier.;J Milot.;J Côté.;J L Malo.;M Laviolette.
来源: Chest. 1998年114卷2期373-9页
Patient evaluation of asthma severity and medication needs is mostly based on respiratory symptoms and may be influenced by changes in perception of bronchoconstriction-induced sensations. However, the influence of asthma medication on the ability to perceive symptoms is still to be documented. This study evaluated the effects of short-term and regular use of salmeterol on the perception of methacholine-induced bronchoconstriction (MIB) in subjects with mild asthma, using inhaled salbutamol on an "as required" basis (n=15), and in subjects with moderate asthma, using daily inhaled beclomethasone (mean daily dose, 640 microg; n=15) in addition to salbutamol to control their asthma.
1072. The effect of adding ipratropium bromide to salbutamol in the treatment of acute asthma: a pooled analysis of three trials.
作者: S F Lanes.;J E Garrett.;C E Wentworth.;J M Fitzgerald.;J P Karpel.
来源: Chest. 1998年114卷2期365-72页
To assess the effect on FEV1 and clinical outcomes of adding ipratropium bromide to salbutamol in the treatment of acute asthma.
1075. Ultrasonographic screening for deep vein thrombosis following arthroplasty fails to reduce posthospital thromboembolic complications: the Postarthroplasty Screening Study (PASS).
作者: D R Anderson.;M Gross.;K S Robinson.;D Petrie.;R Leighton.;W Stanish.;D Alexander.;M Mitchell.;B Flemming.;M Gent.
来源: Chest. 1998年114卷2 Suppl Evidence期119S-122S页 1079. Beneficial effect of atrial natriuretic peptide on pulmonary gas exchange in patients with acute lung injury.
The purpose of this study was to investigate the effect of i.v. infusion of atrial natriuretic peptide (ANP) on hemodynamics, pulmonary gas exchange, and urine volume during mechanical ventilation with positive end-expiratory pressure (PEEP) in patients with acute lung injury.
1080. Beta-blocker effects on respiratory sinus arrhythmia and baroreflex gain in normal subjects.
作者: M V Pitzalis.;F Mastropasqua.;F Massari.;A Passantino.;P Totaro.;C Forleo.;P Rizzon.
来源: Chest. 1998年114卷1期185-91页
The results of studies on the effect of beta-adrenergic blockade on respiratory sinus arrhythmia (RSA) are discordant. The aim of this study was to verify whether chronic beta-adrenergic blockade is capable of increasing RSA, and therefore vagal outflow, and to analyze whether the mechanism of action is central or peripheral.
|